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Abstract
Introduction/Background: In a Phase III, randomized, double-blind placebo-
controlled study conducted in 34 sites from 9 countries, two doses of
abobotulinumtoxinA (Dysport®) 500 and 1000 units (U) were shown to be
efficacious on muscle tone for the treatment of hemiparetic adults post stroke
or traumatic brain injury (TBI) with a favourable safety profile.1. Materials and
Methods: 243 patients received abobotulinumtoxinA 500 or 1000 U or placebo by
intramuscular injection into their primary targeted muscle group (PTMG, selected
from extrinsic finger flexors, wrist flexors and elbow flexors) and at least two other
upper limb muscles, including shoulder muscles. Treatment was administered in
a volume of 5.0 mL using electrostimulation. Doses administered to upper limb
muscles are reported here. Results: For the abobotulinumtoxinA 500 U group,
mean (SD) doses (U) administered in fingers flexors were: 93.5 (17.0) for flexor
digitorium profundus (FDP), 95.4 (14.3) for flexor digitorium s...
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walking distance. Methods: Cross sectional study using thirty pa-
tient moderate and severe COPD (FEV1 30-80, FEV1/FVC < 70) 
aged 60-75 years were randomly assigned to the two groups, in-
tervention and control. The intervention group received standard 
pulmonary rehabilitation, unsupported upper extremity exercise 
and treadmill exercise 3 times a week for 6 week, while control 
group received standard pulmonary rehabilitation and treadmill 
only. The main outcome measure are decrease ADL-time using 
Glittre ADL test and walking distance using 6 minutes walking test 
(MWT). Results: After 6 weeks, patients in the intervention group 
improved in the ability to do ADL with reduce ADL-time to do 
Glittre ADL test compared with those patients in the control group 
(p < 0.05) also they could increase the walking distance from Mini-
mal Important Difference. Conclusion: This study suggest that the 
combination upper and lower extremity exercise improve ability to 
do ADL and walking distance in elderly with moderate and severe 
COPD better than the lower extremity exercise only.
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Objective: Post acute hospitalization falls, among the elderly, were 
rarely discussed. The incidence of anxiety among the elderly is 
around 15%. The aim of this study is to test the association between 
anxiety at time of hospitalization and falls occurring within one-
month post-discharge. And, to offer potential mechanism for this as-
sociation. Method: One month prospective cohort study of 694 older 
adults in two Israeli medical centers. Falls, anxiety and peri hospi-
talization functional decline were assessed. Results: A total of N = 87 
(12.5%) participants reported at least one fall during the 30-day post-
discharge period. Controlling for functional decline, cognitive status, 
chronic and acute illness severity, length of stay, pre-morbid mobility 
and sleep medication consumption; The odds of falls between dis-
charge to 1-month follow-up were 1.73 (95% CI: 1.03-2.91) among 
patients with moderate to high anxiety. Among patients with func-
tional decline by discharge, the odds of falls were 2.18 (95% CI: 
1.12-4.22) for patients with moderate to high anxiety. When account-
ing for functional decline the relationship between falls and anxiety 
was reduced by 14% (from OR = 2.19 to OR = 1.91). Conclusion: 
Anxiety at time of hospitalization is associated with falls 30-days 
post discharge, controlling for several well known confounders. This 
relationship is partially mediated by functional decline. Identifying 
patients with anxiety for inclusion in targeted rehabilitation interven-
tions may be an important component in fall prevention strategies. 
A.7.2 SPASTICITY MANAGEMENT
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Introduction/Background: In a Phase III, randomized, double-blind 
placebo-controlled study conducted in 34 sites from 9 countries, 
two doses of abobotulinumtoxinA (Dysport®) 500 and 1000 units 
(U) were shown to be efficacious on muscle tone for the treatment 
of hemiparetic adults post stroke or traumatic brain injury (TBI) 
with a favourable safety profile.1. Materials and Methods: 243 pa-
tients received abobotulinumtoxinA 500 or 1000 U or placebo by 
intramuscular injection into their primary targeted muscle group 
(PTMG, selected from extrinsic finger flexors, wrist flexors and 
elbow flexors) and at least two other upper limb muscles, includ-
ing shoulder muscles. Treatment was administered in a volume of 
5.0 mL using electrostimulation. Doses administered to upper limb 
muscles are reported here. Results: For the abobotulinumtoxinA 500 
U group, mean (SD) doses (U) administered in fingers flexors were: 
93.5 (17.0) for flexor digitorium profundus (FDP), 95.4 (14.3) for 
flexor digitorium superficialis (FDS) and 76.9 (26.8) for other fin-
ger flexors (flexor pollis longus, adductor pollicis); in wrist flexors: 
92.2 (18.1) for flexor carpi radialis (FCR) and 89.9 (25.7) for flexor 
carpi ulnaris (FCU); in elbow flexors: 88.3 (28.5) for brachioradi-
alis, 148.5 (60.2) for brachialis and 108.6 (49.5) for other elbow 
muscles (biceps brachii, pronator teres) and 122.2 (44.1) in shoulder 
muscles (triceps brachii, pectoralis major, subscapularis, latissimus 
dorsi). For the abobotulinumtoxinA 1000 U group, doses adminis-
tered were 195.5 (25.9) for FDP, 196.8 (28.4) for FDS, 157.0 (53.3) 
for other finger flexors, 178.1 (45.5) for FCR, 171.2 (45.2) for FCU, 
172.1 (44.8) for brachioradialis, 321.4 (103.2) for brachialis, 216.5 
(92.2) for other elbow muscles and 300.0 (129.1) in shoulder mus-
cles. Conclusion: In this Phase III worldwide study in hemiparetic 
patients with upper limb spasticity post stroke/TBI, mean doses 
administered were 76.9–196.8 U for muscles in the finger flexors, 
89.9-178.1 U for muscles in wrist flexors, 88.3–321.4 U for muscles 
in the elbow flexors and 122.2–300.0 U in shoulder muscles. Total 
dose administered (in the PTMG and at least 2 upper limb muscles) 
was 500 or 1000 U, which was previously shown to improve muscle 
tone in this patient population. Reference: Gracies JM, et al. WCNR 
2014; abstract OP-144.
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Background: In the last twenty-five years several studies have dem-
onstrated the efficacy of onabotulinumtoxinA (BoNT-A) injections 
in reducing facial synkinesis. Another common therapeutic option 
that has shown an important role in both the prevention and the 
treatment of facial synkinesis is facial neuromuscular retraining 
with mirror biofeedback (BFB). Despite the great number of studies 
about the efficacy of BoNT-A or BFB separately, in the literature 
there is a paucity of studies about the long-term effects on facial 
function of the combined therapy with repeated BoNT-A injections 
in association with BFB rehabilitation. Aim: to explore the pres-
ence of an acquired improvement of the facial function out of the 
pharmacological effect of BoNT-A in subjects with established fa-
cial palsy, after repeated sessions of BoNT-A injections combined 
with mirror biofeedback rehabilitation. Setting: Outpatient Clinic 
of Physical Medicine and Rehabilitation Unit, Fondazione IRCCS 
Policlinico San Matteo, Pavia, Italy. Population: 27 consecutive 
patients (22 females; mean age 45 ± 16 years) with an established 
facial palsy were treated for facial synkinesis in association with 
mirror biofeedback exercises at home. A minimum of three sessions 
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